1 / 34

Cancer Clinical Trials:

Cancer Clinical Trials:. In-Depth Information. The Drug Development and Approval Process. 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3) 4. NDA filed with FDA 5. FDA validates claim and approves drug.

Faraday
Télécharger la présentation

Cancer Clinical Trials:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cancer Clinical Trials: In-Depth Information

  2. The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3) 4. NDA filed with FDA 5. FDA validates claim and approves drug

  3. Phases of Clinical Trials • Phase 1: 15-30 people • What dosage is safe? • How should treatment be given? • How does treatment affect the body? • Phase 2: Less than 100 people • Does treatment do what it is supposed to? • How does treatment affect the body?

  4. Phases of Clinical Trials • Phase 3: From 100 to thousands of people • Compare new treatment with current standard • Phase 4: From hundreds to thousands of people • Usually takes place after drug is approved • Used to further evaluate long-term safety and effectiveness of new treatment

  5. Types of Clinical Trials • Treatment • Prevention • Screening and early detection • Diagnostic • Genetics • Quality-of-life / supportive care

  6. Treatment Trials • Test safety and effectiveness of new agents or interventions in people with cancer • Possible benefit: • Early access to new treatments • Possible risk: • Occurrence of unknown side effects

  7. Prevention Trials • For people at risk of developing cancer • Action studies vs. agent studies • Possible benefit: • Early access to new interventions • Possible risk: • Unknown side effects and effectiveness

  8. Screening and Early-Detection Trials • Assess new means of detecting cancer earlier in healthy people • Possible benefit: • Detecting disease at an earlier stage, resulting in improved outcomes • Possible risks: • Discomfort and inconvenience • If imaging technique is studied, exposure to x-rays or radioactive substances

  9. Diagnostic Trials • Develop better tools for classifying types and phases of cancer and managing patient care • Possible benefits: • New technology may be better and less invasive • Earlier detection of recurrences • Possible risk: • May require people to take multiple tests

  10. Genetics Trials • These trials seek to: • Determine how one’s genetic makeup can influence detection, diagnosis, prognosis, and treatment • Broaden understanding of causes of cancer • Develop targeted treatments based on the genetics of a tumor

  11. Quality-of-Life / Supportive Care Trials • Aim to improve quality of life for patients and their families • Possible benefit: • Early access to new treatment • Possible risk: • May not benefit from participation

  12. Clinical Trial Protocol A written, detailed action plan that: • Provides background about the trial • Specifies trial objectives • Describes trial’s design and organization • Ensures that trial procedures are consistently carried out

  13. Investigational Drug UseOutside of a Clinical Trial • Group C drugs • Treatment Investigational New Drug application • Compassionate use program

  14. Clinical Trial Design • Eligibility criteria: Can range from general (age, sex, type of cancer) to specific (prior treatment, tumor characteristics, blood cell counts, organ function); eligibility criteria also vary with trial phase • Varies with protocol and phases • Endpoint: Measurable outcome that indicates an intervention’s effectiveness

  15. Clinical Trial Design • Randomization: A method used to prevent bias in research; a computer or a table of random numbers generates treatment assignments, and participants have an equal chance to be assigned to one of two or more groups (e.g., the control group or the investigational group)

  16. Randomization

  17. Clinical Trial Design • Stratification: Categorizing subjects into subgroups by specific characteristics • Enables researchers to look into separate subgroups to see whether differences exist

  18. Stratification

  19. The Final Step: FDA Approval • Review of New Drug Application (NDA) or Biologics License Application (BLA) • Labeling • Continued monitoring • Feedback

  20. Releasing the Results of Clinical Trials • Peer-reviewed journals • Public announcements • Results not made public until end of trial

  21. Improving Cancer Prevention, Detection, and Treatment Once proven safe and effective in a clinical trial, an intervention may become the new standard of care

  22. Advancing Cancer Care • Gleevec for chronic myelogenous leukemia • Cervical cancer: improved survival rates • Breast cancer: less extensive surgery • Intron-A for melanoma • Biological therapy • Monoclonal antibodies • Cancer vaccines

  23. Evolution of Participant Protection • Nuremberg • Tuskegee Syphilis Study • National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research • Belmont Report • National Research Act

  24. Government Oversight of Safeguards for Participants • Office for Human Research Protections (OHRP) • The Common Rule • FDA Regulations

  25. Protecting Participants Before a Trial • Scientific review by sponsoring organization • Institutional review board approval • Informed consent

  26. Protecting Participants During a Clinical Trial • Institutional review boards (IRBs) • Data and safety monitoring boards (DSMBs) • Minimize risks • Ensure integrity of data • Can stop study if necessary

  27. Barriers to, Benefits of, and Risks of Participation in Clinical Trials

  28. Barriers to Adult Participation in Clinical Trials Physicians and other health professionals may: • Be unaware of appropriate trials • Be unwilling to lose control of patient’s care • Believe that standard therapy is best • Believe that clinical trials are more work • Harbor concerns about the patient’s care or how the person will react to suggestion of clinical trial participation

  29. Barriers to Adult Participation in Clinical Trials Patients may: • Be unaware of clinical trials • Lack access to trials • Fear, distrust, or be suspicious of research • Have practical or personal obstacles • Face insurance or cost problems • Be unwilling to go against their physicians’ wishes

  30. Benefits of Participating in Clinical Trials • Early access to new treatments • Active role in own health care • Participation in advancing medical knowledge

  31. Risks of Participating in Clinical Trials • New treatments are not always better than standard care • Unexpected side effects • May not work for everyone • Additional cost

  32. NCI-Sponsored Clinical Trial Programs • Clinical Trials Cooperative Group Program • Clinical Trials Support Unit (CTSU) • Community Clinical Oncology Program (CCOP) • Minority-Based Community Clinical Oncology Program • Cancer Centers Program • Clinical Grants Program

  33. Referring Patients to Clinical Trials Health care professionals should know: • Trial objectives • Eligibility criteria • Treatment and prevention options

  34. Locating NCI Clinical Trials in the Community NCI clinical trial registry: • Nation’s most comprehensive resource on cancer clinical trials • www.cancer.gov • 1-800-4-CANCER (1-800-422-6237)

More Related